NOW APPROVED!
ALTUVIIIO™ is an injectable medicine that is used to control and reduce the number of bleeding
episodes in people with hemophilia A. Come learn about this option for treatment with Sanofi.
Register Here: https://secure.qgiv.com/for/zwpagq/event/sanofi-dinner-event-altuviiio/
A Persuasive Argument for a New Hemophilia A Drug: Revolutionizing Treatment and Transforming Lives
Introduction:
Update about a groundbreaking new drug that has the potential to revolutionize hemophilia A treatment and transform the lives of millions affected by this rare bleeding disorder.
1. Addressing Unmet Needs:
Hemophilia A, a genetic disorder characterized by impaired blood clotting, significantly impacts the quality of life of those who suffer from it. Current treatment options, while effective, are not without limitations. Patients often require frequent intravenous infusions of clotting factor concentrates, which can be time-consuming, burdensome, and pose the risk of inhibitor development. This new hemophilia A drug, however, has the potential to address these unmet needs and improve patient outcomes.
2. Substantial Efficacy:
The clinical trial has demonstrated the striking efficacy of this new drug. By utilizing cutting-edge gene-editing technology, it targets and corrects the genetic mutation responsible for clotting factor VIII deficiency, the underlying cause of hemophilia A.
3. Convenience and Reduced Burden:
One of the most significant advantages of this new drug is its convenience and reduced treatment burden. Unlike traditional treatments, which require regular infusions, this drug has the potential to offer a prolonged therapeutic effect. Administered through a simple, one-time intravenous infusion, patients will experience fewer interruptions to their daily lives. This convenience will not only enhance adherence to treatment but also alleviate the emotional and physical toll that frequent infusions impose on patients and their families.
4. Prevention of Inhibitor Development:
One of the most dreaded complications of current hemophilia A treatment is the development of inhibitors, which neutralize the therapeutic effects of clotting factor concentrates. The promising feature of this new drug is its potential to prevent inhibitor development altogether. By addressing the genetic mutation at its source, it has the capability to provide sustainable and long-lasting clotting factor VIII production, making inhibitors a concern of the past.
5. Cost-Effectiveness:
Although concerns about the cost of novel treatments often arise, it is essential to consider the long-term benefits and potential cost-effectiveness of this new drug. By reducing the frequency of injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A.
You can learn all about Altuviiio here: Patient Website | ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]
Presented By: Jessie Pindilli
Sponsored By:
